<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34919659</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1460-2180</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Carcinogenesis</Title>
          <ISOAbbreviation>Carcinogenesis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>USP53 activated by H3K27 acetylation regulates cell viability, apoptosis and metabolism in esophageal carcinoma via the AMPK signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>349</StartPage>
          <EndPage>359</EndPage>
          <MedlinePgn>349-359</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/carcin/bgab123</ELocationID>
        <Abstract>
          <AbstractText>Esophageal carcinoma (ESCA) is a leading cause of cancer death worldwide, despite an overall decline in the incidence of new cases. However, knowledge of gene expression signatures for risk and prognosis stratification of ESCA is inadequate. Thus, identifying novel molecular biomarkers and therapeutic targets for ESCA might improve its prognosis and treatment. The current study investigated the role of ubiquitin-specific peptidase 53 (USP53), a member of the USP family that exhibits deubiquitinating activity, in ESCA and showed that USP53 is downregulated in ESCA tissues, indicating poor prognosis. USP53 suppresses the proliferation and growth of ESCA cells in vitro and in vivo, whereas its knockdown exerts opposite effects. AMP-activated protein kinase inhibitor reverses the effects of USP53 knockdown. USP53 also inhibits glycolysis, oxidative metabolism and mitochondrial dynamics. H3K27 acetylation increases USP53 expression by binding to its promoter region. Our study reveals that USP53 is activated by H3K27 acetylation and suppresses ESCA progression by regulating cell growth and metabolism. USP53 is therefore a promising target for ESCA treatment.</AbstractText>
          <CopyrightInformation>Â© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematologic and Oncology, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Chinaand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tong</LastName>
            <ForeName>Xiaobin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematologic and Oncology, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematologic and Oncology, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Jingrong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematologic and Oncology, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jinlong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematologic and Oncology, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematologic and Oncology, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ta</LastName>
            <ForeName>Na</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematologic and Oncology, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Zhou</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0001-5537-792X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General surgery, The Center Hospital of Karamay City, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Karamay, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Carcinogenesis</MedlineTA>
        <NlmUniqueID>8008055</NlmUniqueID>
        <ISSNLinking>0143-3334</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.19.12</RegistryNumber>
          <NameOfSubstance UI="C579192">USP53 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.19.12</RegistryNumber>
          <NameOfSubstance UI="D064570">Ubiquitin-Specific Proteases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002277" MajorTopicYN="Y">Carcinoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004938" MajorTopicYN="Y">Esophageal Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064570" MajorTopicYN="N">Ubiquitin-Specific Proteases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>17</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34919659</ArticleId>
        <ArticleId IdType="doi">10.1093/carcin/bgab123</ArticleId>
        <ArticleId IdType="pii">6468900</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
